Modified pegRNAs mitigate scaffold-derived prime editing by-products
Prime editors (PEs) employ reverse transcriptase (RT) to install genomic edits using a template within the prime editing guide RNA (pegRNA). RT creates a 3' genomic flap containing the intended edit. However, reverse transcription can continue beyond the template, incorporating the pegRNA scaffold sequence into the 3' flap. These scaffold-derived by-products can be installed alongside the intended edit, reducing prime editing precision. Here, we develop a method that prevents RT from accessing the scaffold, thereby mitigating such by-products. We demonstrate that an internal abasic spacer or 2'-O-methylation within the pegRNAs terminates RT at the end of the template. This prevents scaffold-derived sequences from being incorporated into the target locus. We benchmark these pegRNAs in different cell types and demonstrate that they can be used with processive PEs such as PE6d or PE**. Our findings provide a simple approach to mitigate a common prime editing by-product and improve prime editing precision.
Authors
- Euan Gordon
- Pei-Pei Hsieh
- Nina Akrap
- Louis Dacquay (ORCID: https://orcid.org/0000-0003-3524-4593)
- Marcello Maresca (ORCID: https://orcid.org/0000-0003-0796-661X)
- George Thom (ORCID: https://orcid.org/0000-0002-1029-3551)
- Saša Šviković (ORCID: https://orcid.org/0000-0002-4149-8453)
- Anna Shiriaeva (ORCID: https://orcid.org/0000-0002-4271-1658)
- Katja Madeyski-Bengtson
- Mike Firth
- Panagiotis Antoniou (ORCID: https://orcid.org/0000-0002-0111-3897)
- Anna-Lena Loyd
- Martin Peterka (ORCID: https://orcid.org/0000-0002-1877-662X)
- Hanna Mårtensson
- Salman Mustfa
Institutions
- AstraZeneca (United Kingdom) (GB)
- Promega (United States) (US)
- AstraZeneca (Singapore) (SG)
- AstraZeneca (Finland) (FI)
- AstraZeneca (Sweden) (SE)
- AstraZeneca (Germany) (DE)
Publication Details
- Journal
- Nature Communications
- Published
- 2025-04-09
- DOI
- https://doi.org/10.1038/s41467-025-58653-1
- Citations
- 6
- Primary Topic
- CRISPR and Genetic Engineering
- Type
- article
- Field-Weighted Citation Impact
- 4.84
Funders
- AstraZeneca
- European Commission
- HORIZON EUROPE Framework Programme